Myriad Genetics, Inc.’s BRACAnalysis® Test Now Enhanced for Exceptionally High-Risk Breast Cancer Patients
Myriad Genetics, Inc. (Nasdaq: MYGN), maker of molecular diagnostic products, has introduced into the market its BRACAnalysis® Rearrangement Test, a new molecular diagnostic test added in the BRACAnalysis family of products.
This additional test detects rare, large rearrangements of the DNA in the BRCA1 and BRCA2 genes and will be performed for women with exceptionally high risk of breast cancer who have tested negative for sequence mutations and the common large rearrangements already included in Myriad’s test.
BRACAnalysis® is Myriad’s test for hereditary breast and ovarian cancer that incorporates the most thorough full-sequence analysis for gene mutation detection ever employed on a broad commercial scale.
“We are very pleased to introduce an exciting and robust technology to detect these rare rearrangement mutations,” said Gregory Critchfield, MD, President of Myriad Genetic Laboratories, Inc.
“This work continues Myriad’s leadership in providing the best testing possible for individuals at risk for hereditary breast and ovarian cancer through our gold-standard BRACAnalysis product.”
Read more at Myriad Genetics, Inc.
Tags: breast-cancer, molecular-diagnostic-testRelated Stories
POSTED IN: on breast cancer, on ovarian cancer
0 opinions for Myriad Genetics, Inc.’s BRACAnalysis® Test Now Enhanced for Exceptionally High-Risk Breast Cancer Patients
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: